The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Highlights: ASCO 2018 oral abstract presentations
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of his favourite oral abstract presentations from this year’s meeting. He speaks about the general themes of the presentations submitted, and then in more detail about the presentations he thought were most relevant to clinical practice. These included studies examining the following: the effect of the IDH1 inhibitor ivosidenib on relapsed/refractory acute myeloid leukemia (AML); the safe treatment of early stage myelodysplastic syndrome (MDS) with low doses of hypomethylating agents; bosutinib vs. the standard of care in chronic myeloid leukemia (CML); and the expansion of NK-cells in the context of HPC transplantation.
